Key result
Cardiovascular events on lipid-modifying therapy drive substantial acute costs, reaching ~£5635 for CABG/PTCA.
Cohort (n=24,093)
The economic burden of cardiovascular events in the UK is substantial, with revascularization and myocardial infarction driving the highest incremental costs, particularly among patients with greater comorbidity.
No takes yet. Share an insight, caveat, or question.
High acute costs from CV events in UK lipid-treated patients; observational data leaves open targeted prevention strategies.
Danese et al. (2016) conducted a cohort in Cardiovascular events (n=24,093). Lipid-modifying therapy was evaluated on Incremental costs, resource usage and total costs per period. Cardiovascular events among UK patients on lipid-modifying therapy resulted in substantial acute incremental costs, highest for CABG/PTCA (£5635) and myocardial infarction (£4275) for first events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: